Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to ...

As of Wednesday, February 18, Cartesian Therapeutics, Inc.’s RNAC share price has dipped by 8.15%, which has investors questioning if this is right time to buy.

This substantial runway provides a buffer as the company navigates the costly clinical trial process. Cartesian operates within a dynamic and evolving segment of the biopharmaceutical industry. A ...

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an ...

Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...